BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 33713286)

  • 21. The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification.
    Cho YK; Kang YM; Yoo JH; Lee J; Lee SE; Yang DH; Kang JW; Park JY; Jung CH; Kim HK; Lee WJ
    Sci Rep; 2018 Aug; 8(1):12004. PubMed ID: 30104707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study.
    Lin A; Wong ND; Razipour A; McElhinney PA; Commandeur F; Cadet SJ; Gransar H; Chen X; Cantu S; Miller RJH; Nerlekar N; Wong DTL; Slomka PJ; Rozanski A; Tamarappoo BK; Berman DS; Dey D
    Cardiovasc Diabetol; 2021 Jan; 20(1):27. PubMed ID: 33514365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study).
    Käräjämäki AJ; Pätsi OP; Savolainen M; Kesäniemi YA; Huikuri H; Ukkola O
    PLoS One; 2015; 10(11):e0142937. PubMed ID: 26571029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes.
    Käräjämäki AJ; Bloigu R; Kauma H; Kesäniemi YA; Koivurova OP; Perkiömäki J; Huikuri H; Ukkola O
    Metabolism; 2017 Jan; 66():55-63. PubMed ID: 27423871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Avillach P; Egger P; Dhalwani NN; Kendrick S; Celis-Morales C; Waterworth DM; Alazawi W; Sattar N
    BMJ; 2019 Oct; 367():l5367. PubMed ID: 31594780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of epicardial fat volume and nonalcoholic fatty liver disease with metabolic syndrome: From the CAESAR study.
    Kim BJ; Kim HS; Kang JG; Kim BS; Kang JH
    J Clin Lipidol; 2016; 10(6):1423-1430.e1. PubMed ID: 27919360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis.
    Mantovani A; Dauriz M; Sandri D; Bonapace S; Zoppini G; Tilg H; Byrne CD; Targher G
    Liver Int; 2019 Apr; 39(4):758-769. PubMed ID: 30657626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atherosclerosis and Associated Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.
    Bajaj S; Prajapati SK
    J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.
    Yoshihisa A; Sato Y; Sato T; Suzuki S; Oikawa M; Takeishi Y
    BMC Cardiovasc Disord; 2018 Jan; 18(1):11. PubMed ID: 29368593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
    Muzurović E; Mikhailidis DP; Mantzoros C
    Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year's prospective cohort study.
    Ryoo JH; Choi JM; Moon SY; Suh YJ; Shin JY; Shin HC; Park SK
    Atherosclerosis; 2013 Apr; 227(2):398-403. PubMed ID: 23390894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance.
    Yang KC; Hung HF; Lu CW; Chang HH; Lee LT; Huang KC
    Sci Rep; 2016 Jun; 6():27034. PubMed ID: 27246655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.
    Targher G; Mantovani A; Pichiri I; Rigolon R; Dauriz M; Zoppini G; Morani G; Vassanelli C; Bonora E
    Clin Sci (Lond); 2013 Sep; 125(6):301-9. PubMed ID: 23596966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and meta-analysis of cohort studies on the potential association between NAFLD/MAFLD and risk of incident atrial fibrillation.
    Zhou BG; Ju SY; Mei YZ; Jiang X; Wang M; Zheng AJ; Ding YB
    Front Endocrinol (Lausanne); 2023; 14():1160532. PubMed ID: 37476492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation.
    Cai X; Zheng S; Liu Y; Zhang Y; Lu J; Huang Y
    Liver Int; 2020 Jul; 40(7):1594-1600. PubMed ID: 32279432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study.
    Zhang T; Zhang C; Zhang Y; Tang F; Li H; Zhang Q; Lin H; Wu S; Liu Y; Xue F
    Atherosclerosis; 2015 May; 240(1):144-8. PubMed ID: 25785362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study.
    Chen YG; Yang CW; Chung CH; Ho CL; Chen WL; Chien WC
    Hepatol Int; 2022 Aug; 16(4):807-816. PubMed ID: 35064545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants.
    Pastori D; Menichelli D; Del Sole F; Pignatelli P; Violi F;
    Mayo Clin Proc; 2021 Mar; 96(3):658-665. PubMed ID: 33308867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation.
    Polovina M; Hindricks G; Maggioni A; Piepoli M; Vardas P; Ašanin M; Ðikic D; Ðuricic N; Milinkovic I; Seferovic PM
    Eur Heart J; 2018 Dec; 39(45):4030-4039. PubMed ID: 30101326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Influence of Epicardial Fat and Nonalcoholic Fatty Liver Disease on Heart Rate Recovery in Metabolic Syndrome.
    Cho KI; Jo EA; Cho SH; Kim BH
    Metab Syndr Relat Disord; 2017 Jun; 15(5):226-232. PubMed ID: 28346857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.